At 2 to 3 mg daily The initiation phase produces the fewest side effects
The medication's formulation is slightly alkaline compared to the skin's natural pH, which may cause transient irritation of subcutaneous tissues and nerve endings
Gastrointestinal adverse events occurred in 79.6% of CagriSema participants versus 39.9% with placebo, were mostly transient, and led to discontinuation in 6-8.4% of participants
The evidence for this is provided by evaluating the liver function biomarkers, CYP2E1 gene expression, iron overload, oxidative stress, SIRT-1 expression and hepatic architecture damage associated with APAP overdose
No claims are made regarding safety, efficacy, or suitability for any specific research application or experimental outcome